GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
- Conditions
- Inflammatory Disease
- Interventions
- Drug: Lanraplenib.
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02959138
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿Auckland Clinical Studies, Grafton, Auckland, New Zealand
🇺🇸Clinical Pharmacology of Miami, Inc. (CPMI), Miami, Florida, United States
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 78
- Registration Number
- NCT02953782
- Locations
- 🇺🇸
Md Anderson, Houston, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 178
- Registration Number
- NCT02953509
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
- Conditions
- Hepatitis C Virus
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1081
- Registration Number
- NCT02951364
- Locations
- 🇰🇷
Busan St. Mary's Hospital, Busan, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷WonKwang University Hospital, Iksan, Korea, Republic of
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo to match cilofexor
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT02943447
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Drug: Placebo to match cilofexor
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT02943460
- Locations
- 🇺🇸
The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇦🇹Universitätsklinik Klinik für Innere Medizin III, Vienna, Austria
🇨🇦University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT02932150
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Auckland, New Zealand
🇷🇴Spitalul Grigore Alexandrescu-Sectia Pediatrie III, Bucharest, Romania
🇷🇴Institutul National de Boli Infectioase "Prof.Dr. Matei Bals", Bucharest, Romania
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1351
- Registration Number
- NCT02914522
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇷🇺State Healthcare Institution "Regional Clinical Hospital", Saratov, Russian Federation
🇷🇺State Autonomous Health Institution of the Tyumen Region "Multidisciplinary Consultative and Diagnostic Center", Tyumen, Russian Federation
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2033
- Registration Number
- NCT02907996
- Locations
- 🇰🇷
Yonsei University Wonju Severance Christian Hospital, Wonju, Gangwon-do, Korea, Republic of
🇰🇷SoonChunHyang University Cheonan Hospital, Cheonan, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Daegu, Korea, Republic of
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT02891408